Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic

Hamšíková, Eva; Ludvı́ková, Viera; Stasikova, Jana; Tachezy, Ruth

doi:10.1136/sextrans-2012-050486

Cited by 12 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study on the prevalence of HPV‐specific antibodies in the general population in the Czech Republic , rates of seropositive females 6–79 years of age were lower than in the present study. A higher prevalence of HPV antibodies and in particular of those to LR HPV types – HPV 6 (3%) and HPV 11 (2%) might be similar to the molecular‐biological findings explained by the difference in the mean age of the subjects between the two studies (23.4 years vs 30.4 years).…”

Section: Discussioncontrasting

confidence: 92%

The prevalence of HPV infections in HPV‐vaccinated women from the general population

Hamšíková

Smahelova

Ludvı́ková

et al. 2017

APMIS

Self Cite

View full text Add to dashboard Cite

Currently, three prophylactic HPV vaccines are commercially available to prevent HPV 16/18 infection and associated lesions. The aim of the study was to assess markers of HPV infection in women/girls before vaccination and to ascertain the prevalence and spectrum of post-vaccination HPV types. Three hundred and thirty subjects of which 75 were virgins were enrolled. Before the first dose of the HPV vaccine and 1, 3 and 5 years after the completion of HPV vaccination, the samples for cytology, HPV detection and anti-HPV antibody response were taken. At enrolment, HPV DNA was detected in 38% of sexually active girls/women. At the first, second and third follow-up, HPV DNA was found in 40, 45, and 39% of them. The seroprevalence rates to HPV 6, 11, 16 and 18 in these subjects were 31, 21, 18 and 10%. On the follow-up significantly higher levels of antibodies to HPV 16/18 were found after application of divalent vaccine. Results of the study demonstrate high prevalence of HPV infection in young women. In a substantial number of women, HPV-specific antibodies as well as high-risk HPV types were detected. HPV-specific antibodies were also frequently found in non-sexually active girls. The acquisition of HPV after the onset of sexual life was very fast.

show abstract

Section: Discussioncontrasting

confidence: 92%

The prevalence of HPV infections in HPV‐vaccinated women from the general population

Hamšíková

Smahelova

Ludvı́ková

et al. 2017

APMIS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another cross-sectional study among women in the Czech Republic demonstrated that 28.5% had any of the four anti-VLPs derived from HPV types 6, 11, 16 or 18. Studies from developing countries show higher rates of HPV seropositivity 19. In Colombia and South Africa the seroprevalence of HPV-16 alone was nearly 45% among women, which is much higher than the present study result 20 21…”

Section: Discussioncontrasting

confidence: 73%

Seroprevalence and awareness of human papillomavirus infection and cervical cancer screening results among reproductive-aged Georgian women

Butsashvili¹,

Abzianidze²,

Kajaia³

et al. 2015

J Fam Plann Reprod Health Care

View full text Add to dashboard Cite

show abstract

“…In this study, the seroprevalence rates for HPV‐6, ‐11, ‐16, and ‐18 in the male partners were more than twice as high as those in men in the general Czech population; in the women the rate was more than three times higher . The higher seroprevalence in the women was not surprising considering that the study was conducted with symptomatic women.…”

Section: Discussionmentioning

confidence: 46%

Concordance of HPV‐DNA in cervical dysplasia or genital warts in women and their monogamous long‐term male partners

Rob

Tachezy

Pichlík

et al. 2017

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Transmission of human papillomavirus (HPV) is a premise for development of cervical dysplasia and genital warts (GWs). This cross-sectional study assesses concordance of HPV types present in GWs or cervical dysplasia in women and genital infection of their monogamous male partners in conjunction with seroprevalence of HPV-6, -11, -16, and -18 antibodies. Blood was taken from both women and men, as well a smear of the urogenital area of men. HPV DNA detection in women was done in fixed paraffin embedded tissues under histological control. Of 143 couples who agreed to participate in the study, 68 met inclusion criteria. Type-specific concordance was observed in 32.5% (13/40) of couples in which women had genital warts and in 32.1% (9/28) of couples in which women had cervical dysplasia. In multivariate analysis only smoking in women was associated with concordance (P < 0.05). Prevalence of HPV-specific antibodies was high in male partners, but was not associated with presence of the same HPV type on their genitals. The same type-specific HPV antibodies were detected in 81.8% of men in couples with HPV-6 concordant genital warts, but only in 14.3% of men in couples with HPV-16 concordant cervical dysplasia (P < 0.01). These results suggest that type-specific HPV concordance in genital warts and cervical dysplasia lesions of women and genital infection of their male partners is common and similar. Higher seroconversion in couples with HPV-6 concordant genital warts compared with couples with HPV-16 concordant cervical dysplasia may be explained by viral load exposure.

show abstract

Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic

Cited by 12 publications

References 29 publications

The prevalence of HPV infections in HPV‐vaccinated women from the general population

The prevalence of HPV infections in HPV‐vaccinated women from the general population

Seroprevalence and awareness of human papillomavirus infection and cervical cancer screening results among reproductive-aged Georgian women

Concordance of HPV‐DNA in cervical dysplasia or genital warts in women and their monogamous long‐term male partners

Contact Info

Product

Resources

About